Leo Wealth LLC Makes New $1.92 Million Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Leo Wealth LLC purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAKFree Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 134,328 shares of the company’s stock, valued at approximately $1,919,000.

A number of other hedge funds have also modified their holdings of TAK. XY Capital Ltd raised its position in Takeda Pharmaceutical by 432.5% during the fourth quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock valued at $10,919,000 after acquiring an additional 621,440 shares in the last quarter. FMR LLC lifted its stake in shares of Takeda Pharmaceutical by 4.7% in the 3rd quarter. FMR LLC now owns 2,593,350 shares of the company’s stock valued at $40,119,000 after purchasing an additional 115,947 shares during the last quarter. Brandes Investment Partners LP boosted its holdings in Takeda Pharmaceutical by 2.1% in the third quarter. Brandes Investment Partners LP now owns 1,802,036 shares of the company’s stock worth $27,877,000 after purchasing an additional 36,717 shares in the last quarter. Citigroup Inc. increased its position in Takeda Pharmaceutical by 5.6% during the third quarter. Citigroup Inc. now owns 57,941 shares of the company’s stock worth $896,000 after buying an additional 3,089 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new position in Takeda Pharmaceutical during the third quarter valued at about $2,105,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 0.5 %

Shares of NYSE:TAK traded up $0.07 on Monday, reaching $13.17. The company had a trading volume of 1,411,766 shares, compared to its average volume of 1,698,642. The company has a quick ratio of 0.58, a current ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $41.68 billion, a P/E ratio of 23.95, a P/E/G ratio of 3.28 and a beta of 0.55. The stock has a 50-day moving average price of $13.27 and a 200 day moving average price of $13.98. Takeda Pharmaceutical Company Limited has a twelve month low of $12.77 and a twelve month high of $16.39.

Takeda Pharmaceutical Company Profile

(Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Recommended Stories

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.